Share price · ALNY
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ALNY's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 29 Oct 2026-25.1%
- 30 Jul 2026-28.3%
- 17 Jul 2026-5.5%
Nothing announced by ALNY that day or the session before.
- 9 Jul 2026-3.3%
Nothing announced by ALNY that day or the session before.
- 17 Apr 2026-3.3%
Nothing announced by ALNY that day or the session before.
- 6 Apr 2026+3.6%
Nothing announced by ALNY that day or the session before.
- 25 Mar 2026+6.7%
Nothing announced by ALNY that day or the session before.
- 17 Feb 2026+5.8%
Nothing announced by ALNY that day or the session before.
- 3 Feb 2026+3.7%
Nothing announced by ALNY that day or the session before.
- 12 Jan 2026-6.9%
Share of unusual movement by asset
For each asset, the share of ALNY's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(15 total)
| Target & Modality | |||
|---|---|---|---|
Fitusiran(Qfitlia) | Approved | Antithrombin (SERPINC1) mRNARNA / oligonucleotide | Hemophilia Hemophilia A and B |
Givosiran(GIVLAARI) | Approved | ALAS1 mRNA (RNAi)RNA / oligonucleotide | Acute Hepatic Porphyria |
Inclisiran(Leqvio) | Approved | PCSK9RNA / oligonucleotide | Atherosclerotic Cardiovascular DiseaseHomozygous Familial Hypercholesterolemia |
Lumasiran(OXLUMO) | Approved | HAO1 (glycolate oxidase)RNA / oligonucleotide | Primary Hyperoxaluria Primary Hyperoxaluria Type 1 |
Patisiran(ONPATTRO) | Approved | Transthyretin (TTR)RNA / oligonucleotide | Transthyretin-Mediated Amyloidosis Transthyretin Amyloidosis with Polyneuropathy |
Vutrisiran(AMVUTTRA) | Approved | Transthyretin (TTR)RNA / oligonucleotide | Transthyretin-Mediated Amyloidosis Transthyretin Amyloidosis with Cardiomyopathy, Transthyretin Amyloidosis with Polyneuropathy |
| Phase 3 | CIDEBRNA / oligonucleotide | MASH / NASH | |
| Phase 3 | Complement C5RNA / oligonucleotide | Age-Related Macular DegenerationMyasthenia Gravis Generalized Myasthenia Gravis | |
| Phase 3 | Transthyretin (TTR)RNA / oligonucleotide | Transthyretin-Mediated Amyloidosis Transthyretin Amyloidosis with Cardiomyopathy, Transthyretin Amyloidosis with Polyneuropathy | |
| Phase 3 | Angiotensinogen (AGT)RNA / oligonucleotide | Hypertension | |
| Phase 2 | PNPLA3RNA / oligonucleotide | MASH / NASH | |
| Phase 2 | APP mRNA (RNAi)RNA / oligonucleotide | Alzheimer's Disease | |
| Phase 2 | HSD17B13RNA / oligonucleotide | MASH / NASH | |
| Phase 1 | MAPT mRNA (RNAi/ASO)RNA / oligonucleotide | Alzheimer's Disease | |
| Phase 1 | Apolipoprotein C-III (APOC3)RNA / oligonucleotide | Atherosclerotic Cardiovascular DiseaseCardiovascular Disease / DyslipidemiaDyslipidemia Hypertriglyceridemia |
Upcoming events
(25 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (7)
January 2027 (1)
What to watch
March 2027 (1)
What to watch
May 2027 (1)
What to watch
August 2027 (3)
December 2027 (1)
What to watch
2028 (7)
February 2028 (1)
What to watch
March 2028 (3)
April 2028 (1)
What to watch
July 2028 (1)
What to watch
October 2028 (1)
What to watch
2029 (5)
2030 (5)
January 2030 (1)
What to watch
March 2030 (1)
May 2030 (2)
September 2030 (1)
What to watch
2032 (1)
March 2032 (1)
What to watch
Regulatory and conference events
(6)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $1.5B | $409M | $1.8B+ $1.8B short-term inv. | —$341M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $1.3B | $413M | $1.7B+ $1.6B short-term inv. | — | report ↗ |
| 2025-Q3 | $1.2B | $359M | $1.5B+ $1.2B short-term inv. | —$325M operating cash flow | report ↗ |
| 2025-Q2 | $774M | $324M | $1.1B+ $1.7B short-term inv. | $66M$154M operating cash flow | report ↗ |
| 2025-Q1 | $594M | $265M | $1.0B+ $1.6B short-term inv. | $57M-$118M operating cash flow | report ↗ |
| 2024-Q3 | $501M | $271M | $1.1B+ $1.7B short-term inv. | $112M$44M operating cash flow | report ↗ |
| 2024-Q2 | $660M | $294M | $971M+ $1.6B short-term inv. | $17M$124M operating cash flow | report ↗ |
| 2024-Q1 | $494M | $261M | $685M+ $1.7B short-term inv. | $66M-$82M operating cash flow | report ↗ |
| 2023-Q3 | $751M | $253M | $1.0B+ $1.4B short-term inv. | —$359M operating cash flow | report ↗ |
| 2023-Q2 | $319M | $249M | $660M+ $1.4B short-term inv. | $276M-$59M operating cash flow | report ↗ |
| 2023-Q1 | $319M | $231M | $674M+ $1.4B short-term inv. | $174M-$166M operating cash flow | report ↗ |
| 2022-Q3 | $264M | $245M | $1.1B+ $1.2B short-term inv. | $406M-$115M operating cash flow | report ↗ |
| 2022-Q2 | $225M | $206M | $578M+ $1.5B short-term inv. | $277M-$123M operating cash flow | report ↗ |
| 2022-Q1 | $213M | $170M | $536M+ $1.7B short-term inv. | $240M-$171M operating cash flow | report ↗ |
| 2021-Q3 | — | $195M | $1.1B+ $1.2B short-term inv. | $205M-$134M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $3.7B | $1.3B | $1.7B+ $1.3B short-term inv. | —$524M operating cash flow | report ↗ |
Alnylam reported full-year 2025 total revenues of $3,713.94M, up 65.2% YoY, with GAAP net income of $313.75M. R&D spend was $1,319.78M, up 17.2% YoY. Cash and equivalents were $1,658.81M, and cash, cash equivalents and marketable securities totaled $2.91B as of December 31, 2025.
For 2026, the company guided to total net product revenues of $4,900M-$5,300M, including TTR product revenues of $4,400M-$4,700M and Rare product revenues of $500M-$600M, with collaboration and royalty revenues of $400M-$500M and non-GAAP R&D and SG&A expenses of $2,700M-$2,800M. The company launched its Alnylam 2030 strategy and announced 2026 pipeline goals including four clinical readouts, three ongoing pivotal studies, three Phase 2 initiations, and three or more new IND filings. Recent progress included the initiation of Phase 2 ALN-4324 in type 2 diabetes, Phase 1 ALN-2232 in obesity, advancement of ALN-4285 and ALN-4915 into clinical development, and a planned $250M expansion of its Norton, Massachusetts manufacturing facility using the siRELIS platform.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $2.2B | $1.1B | $969M+ $1.7B short-term inv. | $70M-$8.3M operating cash flow | report ↗ |
| 2023-FY | $1.8B | $1.0B | $815M+ $1.6B short-term inv. | $110M$104M operating cash flow | report ↗ |
| 2022-FY | $1.0B | $883M | $869M+ $1.3B short-term inv. | $283M-$541M operating cash flow | report ↗ |
| 2021-FY | $844M | $792M | $822M+ $1.5B short-term inv. | $213M-$642M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 2 purchases ($543K), 248 sales ($26.9M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-13 | Greenstreet Yvonne · director, Chief Executive Officer | Gift | 11,000 | — | — | Form 4 |
| 2026-11-10 | Sigal Charles Elliott · director | Open-market purchase | 1,600 | $152.25 | $244K | Form 4 |
| 2026-11-10 | PYOTT DAVID E I · director | Option exercise | 3,780 | $71.99 | $272K | Form 4 |
| 2026-11-10 | PYOTT DAVID E I · director | Option exercise (derivative) | 3,780 | — | — | Form 4 |
| 2026-11-09 | SCHULMAN AMY W · director | Open-market purchase | 1,910 | $156.82 | $300K | Form 4 |
| 2026-10-02 | SUPRAN BRYAN · EVP, CLO and Secretary | Open-market sale | 1,758 | $226.88 | $399K | Form 4 |
| 2026-09-19 | Greenstreet Yvonne · director, Chief Executive Officer | Award / grant | 107 | — | — | Form 4 |
| 2026-06-01 | Cravatt Benjamin · director | Award / grant (derivative) | 4,393 | — | — | Form 4 |